View: India should attract Chinese investment even while checking it strategically

Without making big national headlines, China’s Gland Pharma launched the biggest initial public offering (IPO) of shares in Indian pharmaceutical history of Rs 6,500 crore in November. This was oversubscribed more than twice, despite calls for boycotting everything Chinese after the Ladakh clash last summer when 20 Indian soldiers died.

Gland Pharma’s issue price was Rs 1,500. Far from being shunned by Indian investors, the share price has now shot up to Rs 2,425. The company has eight factories in India and dozens across the world. It makes drug formulations for consumers as well as active pharmaceutical ingredients (APIs) needed by Indian pharma companies. India imports most APIs from China, and has recently announced a productivity-linked scheme to increase API production in India to reduce dependence on China.

Read more

You may also like

More in IT

Comments are closed.